Soy-Based Breast Implants; May Cause Toxic Reactions Including Cancer (Old news never realeased?)

[Guest guest]

Lawsuit Filed Today Against Makers of Soy-Based Trilucent Breast Implants; May Cause Toxic Reactions Including Cancer - At least one victim available for interview

Business Editors/Health & Medical Writers

MIAMI--(BUSINESS WIRE)--Aug. 10, 2000

http://findarticles.com/p/articles/mi_m0EIN/is_/ai_63987117

Miami attorney Jeffrey Herman filed a products liability suit in a California Federal Court today against five U.S. companies that developed, manufactured and/or sold the potentially dangerous Trilucent breast implants filled with soya oil and used in approximately 9,000 procedures conducted in the UK and Europe. The latest scientific data shows that this type of implant may be harmful according to the Medical Devices Agency (MDA) in the U.K. and according to Professor Kevin Chipman of the Committee on Toxicology it could potentially cause cancer.

 

 

 

Related Results

Trust, E-innovation and Leadership in Change

Foreign Banks in United States Since World War II: A Useful Fringe

Building Your Brand With Brand Line Extensions

The Impact of the Structure of Debt on Target Gains

Project Management Standard Program

Although approved with the European CE quality mark by TUV Munich, a privately owned company based in Germany, research indicates that the oil can and does leak from the implants, and that toxic products created when the oil deteriorates are harmful and potentially cancerous. In 1999, Dr. S. Montrey with the Department of Plastic Surgery at University Hospital in Belgium released a report called "Biocompatibility and Oxidative Stability of Radiolucent Breast Implants," which showed that when the soy implants leak, lipid peroxides are formed and turn into toxins in the body. Based upon that and other research, this year, the British government warned that the implants should be removed. The implants, which were not approved by the Food and Drug Administration (FDA) and therefore unavailable in the U.S., were withdrawn from sale in the UK in 1999 and so far approximately 2,000 women have had them removed.

The five defendants named in the case are: AEI, an American company formerly known as Collagen Aesthetics Inc.; Inamed Corp., a public company; Cohesion Technologies, Inc., a public company; TUV, the company that approved the implant for sale with its CE stamp; Washington University at St. Louis, where the product was invented, patented and sold, and LipoMatrix, Inc., a British Virgin Islands company with U.S. offices that manufactured the implant.

"With the knowledge we have on the dangers caused by breast implants, it was unconscionable to put so many women at risk," said Jeffery Herman, managing partner at the Miami-based law firm of Herman & Mermelstein, P.A. "It is heart-wrenching to think that many of the women who received these implants and have been put at risk of developing cancer did so after having successful mastectomies to remove breast cancer."

Approximately 5,000 of the women who received the implants are thought to be in the UK. The remainder are spread out across Europe and the U.S. A number of American women traveled overseas for the procedure.

Herman will be in London on Thursday, Aug. 17 - Saturday, Aug. 19 at the Ritz Hotel to answer questions about the dangerous Trilucent Breast Implants. Call Herman's international toll free number 0800 0152795 for information or to schedule an appointment during that time. You may also email Herman at trilucentclaims or visit the Web Site www.trilucentclaims.com. In the U.S. Herman can be reached at 305-377-2200.

Herman & Mermelstein P.A. is a boutique Miami-based law firm that focuses on litigation and aviation matters.